BISC Global receives half a million euros to develop ML-based suite for accelerated antibody discovery and design

BISC Global, a leading Bioinformatics, Biostatistics, and AI/ML consulting company with six offices in Europe and US, received €0.5 million funding from Flanders Innovation & Entrepreneurship (VLAIO) for the project “AbSuite – Machine learning-based methods for antibody discovery and design”. The goal of this project is to develop a comprehensive software suite that will accelerate the bench-to-beside process for therapeutic monoclonal antibodies (mAbs).

Antibody-based therapeutics can be used to treat many diseases, such as cancer and immune diseases, with precision and efficiency surpassing traditional treatments. As a result, therapeutic antibodies are the fastest-growing class of drugs on the market. Yet, the discovery and design of new antibody drug candidates are time-consuming, inefficient, and cost-intensive. To change that, BISC Global will build AbSuite, a suite of machine learning applications that will accelerate the antibody discovery and development process, for example, by guaranteeing a lower failure rate in the development phase.  

Antibody discovery companies will be able to use AbSuite discovery model to obtain novel leads. The phage library design algorithm in AbSuite will moreover allow them to improve the efficiency of their in vitro discovery efforts 

Pharmaceutical companies will benefit from AbSuite’s humanization and developability models to optimize promising antibody leads 

To create AbSuite, BISC Global will use its extensive in-house expertise in domains spanning bioinformatics, AI, and immunology with its established network of experts in the field, both in the industry as well as in academia. Following the successful development of AbSuite, BISC Global aspires to make this ML-based suite part of the standard preclinical procedure for discovering and developing monoclonal antibodies. 

About BISC Global

Founded in 2017, BISC Global has grown to be a Top 10 Bioinformatics Consulting and Services Firm supporting world’s leading pharmaceutical and biotech companies. Through our offices in Belgium, Switzerland, The Netherlands, Germany, and the US (Boston, MA; and San Francisco, CA); BISC Global provides data analytics, custom tool/pipeline development, and cloud solutions delivered on-site or remotely. By leveraging our global workforce of expert consultants, we support analysis across multiple domains, including machine learning (data mining, pattern recognition, image analysis, (un)supervised learning, neural networks, deep learning, etc.), bioinformatics (single-cell transcriptomics, metabolomics, metagenomics, epigenomics, etc.), and statistics (experimental design, mathematic modeling, signal-to-noise enhancement, and independent data cross-validation).

For more information, please send us an email at

If you are working in antibody therapeutics design & development and would like to learn more about AbSuite, get in touch with us!